By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Alder Biopharmaceuticals Inc. 

Corporate Headquarters
11804 North Creek Parkway South
Bothell  Washington  98011  U.S.A.
Phone: 425-205-2900 Fax: 425-205-2901


SEARCH JOBS

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, ALD403, is being evaluated for migraine prevention. ALD403 is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

At Alder we seek talented contributors who thrive in a high-energy team environment and want to make a real and lasting impact in the field of antibody therapeutics. Alder teams are creative, collaborative, open, committed--and central to the success of this company and its mission. If this is the kind of company you want to work for, we want to hear from you.


Key Statistics


Email: info@alderbio.com
Ownership: Private

Web Site: Alder Biopharma
Employees:
Symbol: 
 




Segment
Pharmaceuticals





Company News
Alder Biopharma To Present Migraine Prevention Data For Eptinezumab At 59th Annual Scientific Meeting Of The American Headache Society 6/8/2017 8:27:26 AM
Alder Biopharma Presents Positive Phase IIb Study Data For Eptinezumab At 69th Annual American Academy of Neurology Meeting 5/1/2017 8:10:38 AM
Alder Biopharma Announces First Quarter 2017 Financial And Operating Results 4/28/2017 8:00:53 AM
Alder Biopharma Presents Additional Data From Eptinezumab Development Program At 69th Annual American Academy of Neurology Meeting 4/24/2017 8:23:39 AM
Alder Biopharma To Host Conference Call To Discuss First Quarter 2017 Financial And Operating Results 4/20/2017 8:07:06 AM
10 Biotech Stocks that Could Blow Up in Q3 7/6/2016 6:56:11 AM
Amgen (AMGN) Shows Off Mid-Stage Migraine Data, Needs to Compete With Eli Lilly (LLY), Teva (TEVA) and Alder Biopharma 6/9/2016 5:54:09 AM
Alder Biopharma Appoints Roger Cady, M.D., Vice President Of Neurology 6/6/2016 3:59:30 PM
Alder Biopharma To Hold Conference Call On Monday, March 28, At 8:30 Am ET 3/28/2016 8:01:20 AM
Alder Biopharma's Migraine Drug Meets Primary and Secondary Endpoints in Phase 2b Trial 3/28/2016 6:34:33 AM
12345678
//-->